Neotack 300 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Ranitidine hydrochloride |
| Company | Square pharmaceuticals plc |
| Also available as |
Indications
- Treatment of active duodenal ulcer
- Benign gastric ulcer
- Ulcer associated with non-steroidal anti-inflammatory agent
- Post operative stress ulcer
- Zollinger-Ellison Syndrome
- Gastroesophageal reflux disease (GERD)
Pharmacology
Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
Dosage & Administration
- 150 mg twice daily for duodenal and gastric ulcer
- Reflux oesophagitis: 150 mg twice daily or 300 mg at bedtime
- Zollinger Ellison syndrome: 150 mg 3 times daily
- Episodic dyspepsia: 150 mg twice daily or 300 mg at bedtime
- Child (peptic ulcer): 2-4 mg/kg twice daily
- Ranitidine injection may be given intravenously or intramuscularly
Interaction
Delayed absorption and increased peak serum concentration with propantheline bromide. May alter absorption of pH-dependent drugs. May reduce bioavailability with antacids.
Contraindications
Patients hypersensitive to Ranitidine
Side Effects
- Altered bowel habit
- Dizziness
- Rash
- Tiredness
- Reversible confusional states
- Headache
- Decreased blood counts
- Muscle or joint pain
Pregnancy & Lactation
- Ranitidine crosses the placenta
- Excreted in human breast milk
Precautions & Warnings
Neotack should be given in reduced dosage to patients with impaired renal and hepatic function.
Use in Special Populations
Ulcer healing rates have been found similar in elderly patients as in younger patients. No difference in the incidence of adverse effects.
Overdose Effects
No particular problems expected following overdosage. Symptomatic and supportive therapy should be given as appropriate.
Therapeutic Class
H2 receptor antagonist
Reconstitution
- Neotack 50 mg diluted to a concentration ≤2.5 mg/mL for slow IV inj
- Neotack 50 mg diluted to a concentration ≤0.5 mg/mL for intermittent slow IV infusion
Storage Conditions
Store in a cool and dry place. Protect from light.